
News|Articles|June 27, 2025
Jennifer Lai, MD, on Counseling Patients About Liver-Healthy Nutrition
Author(s)Jennifer Lai, MD
Fact checked by: Lana Pine
Jennifer Lai, MD, shares science-backed strategies for clinicians to counsel patients on nutrition and liver health.
Advertisement
Advertisement
As the global burden of fatty liver disease continues to rise, clinicians are increasingly turning to nutrition-based interventions as frontline management. In this final installment of our liver health series in partnership with the
Related to this article

The Liver Keeps the Score: Americans Are Drinking Less, but Alcohol-Associated Liver Disease May Lag
Drinking fell for the first time since COVID-19, but not for adults 50 to 64. Hepatologists explain what clinicians can do to close the gap.

As drinking declines, Stevan Gonzalez, MD, Frances Lee, MD, and Brian Lee, MD, on the lingering burden of alcohol-associated liver disease.

Patients with obesity or overweight and T2D saw substantially greater mean weight loss and HbA1c improvement with petrelintide versus placebo.

Remibrutinib doubled complete Total Fric Score response vs placebo at week 12 in RemIND, becoming the first therapy approved specifically for SD.

Presented at EASD 2026, the present analysis discusses CBL-514’s apparent efficacy in reducing L2-L3 visceral fat compared to placebo.

A hepatologist on the lag between drinking and liver disease, metabolic risk, prevention gaps, and when the burden may peak.

Nephrology in Q3 2026: FDA approvals for atacicept, iptacopan, finerenone, and obinutuzumab, plus 2-year IgAN data and CKD screening.
Advertisement
Advertisement

